ATRA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.2M
+94.3%
630.0K
+22.1%
516.0K
-67.6%
1.6M
-53.8%
3.5M
Cost of Revenue
265.0K
+38.7%
191.0K
+54.0%
124.0K
+19.2%
104.0K
-9.6%
115.0K
Gross Profit
959.0K
+118.5%
439.0K
+12.0%
392.0K
-73.7%
1.5M
-55.3%
3.3M
Operating Expenses
3.9M
-23.8%
5.2M
+37.2%
3.8M
-7.2%
4.1M
-41.3%
6.9M
R&D
1.1M
-18.3%
1.3M
+720.1%
164.0K
+173.5%
-223000
-107.6%
2.9M
SG&A
2.8M
-25.8%
3.8M
+6.0%
3.6M
-15.9%
4.3M
+7.3%
4.0M
Operating Income
-2970000
+37.1%
-4720000
-40.1%
-3369000
-31.4%
-2563000
+28.3%
-3574000
EBITDA
-2967000
+37.0%
-4706000
-40.9%
-3340000
-32.9%
-2514000
+28.9%
-3538000
Net Income
-2229000
+53.9%
-4834000
-16.6%
-4145000
-21.7%
-3406000
+20.8%
-4303000
EPS (Basic)
$-0.15
+53.1%
$-0.32
-10.3%
$-0.29
-16.0%
$-0.25
+21.9%
$-0.32
EPS (Diluted)
$-0.15
+53.1%
$-0.32
-10.3%
$-0.29
-20.8%
$-0.24
+25.0%
$-0.32
Shares (Diluted)
15.3M
+1.9%
15.0M
+6.8%
14.1M
-0.5%
14.1M
+4.3%
13.6M
Atara Biotherapeutics (ATRA) — Financials